Revenue Breakdown
Composition ()
No data
Revenue Streams
Assertio Holdings Inc (ASRT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ROLVEDON, accounting for 78.0% of total sales, equivalent to $38.57M. Other significant revenue streams include INDOCIN products and Sympazan. Understanding this composition is critical for investors evaluating how ASRT navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Assertio Holdings Inc maintains a gross margin of 61.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.09%, while the net margin is 23.14%. These profitability ratios, combined with a Return on Equity (ROE) of -24.48%, provide a clear picture of how effectively ASRT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ASRT competes directly with industry leaders such as ENTX and PYPD. With a market capitalization of $74.05M, it holds a significant position in the sector. When comparing efficiency, ASRT's gross margin of 61.08% stands against ENTX's 0.00% and PYPD's N/A. Such benchmarking helps identify whether Assertio Holdings Inc is trading at a premium or discount relative to its financial performance.
